JP2023514242A5 - - Google Patents

Info

Publication number
JP2023514242A5
JP2023514242A5 JP2022548941A JP2022548941A JP2023514242A5 JP 2023514242 A5 JP2023514242 A5 JP 2023514242A5 JP 2022548941 A JP2022548941 A JP 2022548941A JP 2022548941 A JP2022548941 A JP 2022548941A JP 2023514242 A5 JP2023514242 A5 JP 2023514242A5
Authority
JP
Japan
Prior art keywords
sequence
nucleic acid
acid molecule
seq
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022548941A
Other languages
English (en)
Japanese (ja)
Other versions
JP7728772B2 (ja
JP2023514242A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/017950 external-priority patent/WO2021163556A1/en
Publication of JP2023514242A publication Critical patent/JP2023514242A/ja
Publication of JP2023514242A5 publication Critical patent/JP2023514242A5/ja
Application granted granted Critical
Publication of JP7728772B2 publication Critical patent/JP7728772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022548941A 2020-02-12 2021-02-12 遺伝子発現の誘導性選択的スプライシング調節のための組成物および方法 Active JP7728772B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062975400P 2020-02-12 2020-02-12
US62/975,400 2020-02-12
PCT/US2021/017950 WO2021163556A1 (en) 2020-02-12 2021-02-12 Compositions and methods for inducible alternative splicing regulation of gene expression

Publications (3)

Publication Number Publication Date
JP2023514242A JP2023514242A (ja) 2023-04-05
JP2023514242A5 true JP2023514242A5 (https=) 2024-02-21
JP7728772B2 JP7728772B2 (ja) 2025-08-25

Family

ID=77292961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548941A Active JP7728772B2 (ja) 2020-02-12 2021-02-12 遺伝子発現の誘導性選択的スプライシング調節のための組成物および方法

Country Status (9)

Country Link
US (1) US20230340498A1 (https=)
EP (1) EP4103717A4 (https=)
JP (1) JP7728772B2 (https=)
KR (1) KR20220146501A (https=)
CN (1) CN115605596A (https=)
AU (1) AU2021218807A1 (https=)
CA (1) CA3167836A1 (https=)
IL (1) IL295542A (https=)
WO (1) WO2021163556A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210355509A1 (en) * 2018-08-07 2021-11-18 The Children's Hospital Of Philadelphia Alternative splicing regulation of gene expression and therapeutic methods
US20250129390A1 (en) * 2021-09-30 2025-04-24 Osaka University Method for producing cell having dna deletion specific to one of homologous chromosomes
EP4419692A4 (en) * 2021-10-22 2025-10-01 Fred Hutchinson Cancer Center SYNTHETIC INTRONS FOR TARGETED GENE EXPRESSION
US20250303000A1 (en) 2022-05-18 2025-10-02 The Children's Hospital Of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression
WO2024060205A1 (zh) * 2022-09-23 2024-03-28 北京基驭医疗科技有限公司 包含基于小分子药物的可变剪接调节元件的核酸分子
EP4627095A2 (en) * 2022-11-28 2025-10-08 Siren Biotechnology, Inc. Gene therapy vectors for treatment of cancer
WO2024173699A2 (en) * 2023-02-16 2024-08-22 Mammoth Biosciences, Inc. Compositions for the treatment of spinal muscular atrophy
WO2024186892A2 (en) * 2023-03-06 2024-09-12 The Children's Hospital Of Philadelphia Regulated control of rna interference by alternative splicing
EP4701634A1 (en) 2023-04-28 2026-03-04 Kriya Therapeutics, Inc. Riboswitches for regulating gene expression and therapeutic methods of using the same
WO2024251925A1 (en) 2023-06-09 2024-12-12 F. Hoffmann-La Roche Ag Inducible gene expression system

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838657B2 (en) * 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
GB2443186A (en) * 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
WO2009151546A2 (en) * 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
DK2812004T3 (en) * 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
ES2771862T3 (es) * 2013-10-28 2020-07-07 Invectys Una vacuna de ADN que codifica telomerasa
CN108603230A (zh) * 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
EA201991309A1 (ru) * 2016-11-28 2019-11-29 Способы модуляции сплайсинга рнк
US20210355509A1 (en) * 2018-08-07 2021-11-18 The Children's Hospital Of Philadelphia Alternative splicing regulation of gene expression and therapeutic methods
EP4004213A1 (en) * 2019-07-25 2022-06-01 Novartis AG Regulatable expression systems
WO2022204471A1 (en) * 2021-03-26 2022-09-29 Ptc Therapeutics Inc. Regulation of transgene expression using a small molecule inducible splicing switch

Similar Documents

Publication Publication Date Title
JP2023514242A5 (https=)
JP2021532812A5 (https=)
JP2022508182A5 (https=)
CN109069672B (zh) 腺相关病毒载体传递微肌营养不良蛋白以治疗肌营养不良症
JP2024009857A5 (https=)
US10392632B2 (en) AAV8 vector with enhanced functional activity and methods of use thereof
JP2022551986A5 (https=)
JP2023534999A5 (https=)
JP2020533959A5 (https=)
JP2022547197A5 (https=)
JP7541027B2 (ja) 筋肉発現のためのハイブリッドプロモーター
JP2023537625A5 (https=)
JP2023500793A5 (https=)
US20020076754A1 (en) Overcoming AAV vector size limitation through viral DNA hetero-dimerization
JP2017529395A5 (https=)
JP2022551744A5 (https=)
JP2023537358A5 (https=)
US12534741B2 (en) Compositions and methods for treatment of neurological disorders
CN119403823A (zh) 具有增强的肌肉转导效率的肽修饰的aav衣壳
JP2024530023A5 (https=)
JP2021534766A5 (https=)
JP2022545378A5 (https=)
JP2023542131A5 (https=)
JP2024515626A5 (https=)
JP2023551254A5 (https=)